Inhibition of melanoma tumor growth by a pharmacological inhibitor of MetAP-2, PPI-2458

International Journal of Oncology

Volumn 28, Issue 4, 2006, Pages 955-963

  Hannig, Gerhard ^a   Lazarus, Douglas D ^a,b   Bernier, Sylvie G ^a   Karp, Russell M ^a   Lorusso, Jeanine ^a   Qiu, Daniel ^a   Labenski, Matthew T ^a   Wakefield, Jim D ^a,c   Thompson, Charles D ^a,d   Westlin, William F ^a  

^a Praecis Pharmaceuticals Incorporated   (United States)

^b PharmaMar USA Inc   (United States)

^c Microbia PE Inc   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Enzyme inhibition; Melanogenesis; Melanoma; MetAP 2; PPI 2458

Indexed keywords

AMINOPEPTIDASE; CDKN1A PROTEIN, MOUSE; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DRUG DERIVATIVE; EPOXIDE; GLYCOPROTEIN; MELANIN; METAP2 PROTEIN, MOUSE; METHIONYL AMINOPEPTIDASE; PPI 2458; VALINE;

ANIMAL; ARTICLE; C57BL MOUSE; CELL LINE; CELL PROLIFERATION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL MELANOMA; HUMAN; MALE; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PATHOLOGY; SECRETION; TUMOR CELL LINE; WESTERN BLOTTING;

ADMINISTRATION, ORAL; AMINOPEPTIDASES; ANIMALS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXY COMPOUNDS; GLYCOPROTEINS; HUMANS; MALE; MELANINS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; VALINE;

EID: 33744740720     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.4.955     Document Type: Article

References (50)

1. Chudnovsky Y, Khavari PA and Adams AE: Melanoma genetics and the development of rational therapeutics. J Clin Invest 115: 813-824, 2005.
2. Tarhini AA and Agarwala SS: Novel agents in development for the treatment of melanoma. Expert Opin Invest Drugs 14: 885-892, 2005.
3. Eggermont AM and Kirkwood JM: Reevaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40: 1825-1836, 2004.
4. Serrone L, Zeuli M, Sega FM and Cognetti F: Dacarbazine-based chemotherapy for metastatic melanoma: thirty year experience overview. J Exp Clin Cancer Res 19: 21-34, 2000.
5. Agarwala S: Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way. Am J Clin Dermatol 4: 333-346, 2003.
6. Nestle M and Carol H: Melanoma. In: Dermatology. Bolognia J, Jorizzo J and Rapini R (eds). Mosby, New York, pp1789-1815, 2003.
7. Margolin KA: Biochemotherapy for melanoma: rational therapeutics in the search for weapons of melanoma destruction. Cancer 101: 435-438, 2004.
8. Bellone M, Cantarella D, Castiglioni P, et al: Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J Immunol 165: 2651-2656, 2000.
9. Bronte V, Apolloni E, Ronca R, et al: Genetic vaccination with 'self' tyrosinase-related protein 2 causes melanoma eradication but not vitiligo. Cancer Res 60: 253-258, 2000.
10. Chen Y-T, Stockert E, Tsang S, Coplan KA and Old LJ: Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci USA 92: 8125-8129, 1995.
11. Mitchell MS, Darrah D, Yeung D, et al: Phase I trial of adoptive immunotherapy with cytolytic T lymphocytes immunized against a tyrosinase epitope. J Clin Oncol 20: 1075-1086, 2002.
12. Sakai C, Kawakami Y, Law LW, Furumura M and Hearing VJ Jr: Melanosomal proteins as melanoma-specific immune targets. Melanoma Res 7: 83-95, 1997.
13. Griffith EC, Su Z, Turk BE, et al: Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin. Chem Biol 4: 461-467, 1997.
14. Sin N, Meng L, Wang MQW, Wen JJ, Bornmann WG and Crews CM: The anti-angiogenic agent fumagillin binds and inhibits the methionine aminopeptidase, MetAP-2. Proc Natl Acad Sci USA 94: 6099-6103, 1997.
15. Liu S, Widom J, Kemp CW, Crews CM and Clardy J: Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science 282: 1324-1327, 1998.
16. Bernier SG, Taghizadeh N, Thompson CD, Westlin WF and Hannig G: Methionine aminopeptidases type I and type II are essential to control cell proliferation. J Cell Biochem 95: 1191-1203, 2005.
17. Bernier SG, Lazarus DL, Clark E, Doyle B, Labenski MT, Thompson CD, Westlin WF and Hannig G: A methionine aminopeptidase-2 inhibitor, PPI-2458, for the treatment of rheumatoid arthritis. Proc Natl Acad Sci USA 101: 10768-10773, 2004.
18. Gruber JR, Ohno S and Niles RM: Increased expression of protein kinase Cα plays a key role in retinoic acid-induced melanoma differentiation. J Biol Chem 267: 13356-13360, 1992.
19. Turk B, Griffith EC, Wolf S, Biemann K, Chang YH and Liu JO: Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells. Chem Biol 4: 823-833, 1999.
20. CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci USA 97: 12782-12787, 2000.
21. Zhang Y, Griffith, EC, Sage J, Jacks T and Liu JO: Cell cycle inhibition by the anti-angiogenic compound TNP-470 is mediated by p53 and p21CIP/WAF. Proc Natl Acad Sci USA 97: 6427-6432, 2000.
22. Melnikova VO, Bolshakov SV, Walker C and Ananthaswamy HN: Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines. Oncogene 23: 2347-2356, 2004.
23. Busca R, Bertoletto C, Ortonne J-P and Balotti R: Inhibition of the phosphatidylinositol 3-kinase/p70S6-kinase pathway induces B16 melanoma cell differentiation. J Biol Chem 271: 31824-31830, 1996.
24. Gaggioli C, Busca R, Abbe P, Ortonne J-P and Balotti R: Microphthalmia-associated transcription factor (MITF) is required but not sufficient to induce expression of melanogenic genes. Pigment Cell Res 16: 374-382, 2003.
25. KIP1 to CDKs, loss of E2F-binding activity, and premature senescence of human melanocytes. Exp Cell Res 253: 561-572, 1999.
26. Hearing VJ and Jimenez M: Mammalian tyrosinase - the critical regulatory control point in melanocyte pigmentation. Int J Biochem 19: 1141-1147, 1987.
27. Hearing VJ and Jimenez M: Analysis of mammalian pigmentation at the molecular level. Pigment Cell Res 2: 75-85, 1989.
28. Bernier SG, Westlin WF and Hannig G: Fumagillin class inhibitors of methionine aminopeptidase-2. Drugs Future 30: 497-508, 2005.
29. Wang J, Lou P and Henkin J: Selective inhibition of endothelial cell proliferation by fumagillin is not due to differential expression of methionine aminopeptidases. J Cell Biochem 77: 465-473, 2000.
30. Datta B, Mjumdar A, Datta R and Balusu R: Treatment of cells with the angiogenic inhibitor fumagillin results in increased stability of eukaryotic initiation factor-2 associated glycoprotein, p67, and reduced phosphorylation of extracellular signal-regulated kinases. Biochemistry 43: 14821-14831, 2004.
31. Nagase T, Miyajima N, Tanaka A, Sazuka T, et al: Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA Res 2: 37-43, 1995.
32. Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature 417: 949-954, 2002.
33. Calipel A, Lefevre G, Pouponnot C, Mouriaux F, Eychene A and Mascarelli F: Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway. J Biol Chem 278: 42409-42418, 2003.
34. Goydos JS, Mann B, Kim HJ, et al: Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 200: 362-370, 2005.
35. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M and Tuveson D: Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202, 2003.
36. Karasarides M, Chiloeches A, Hayward R, et al: B-RAF is a therapeutic target in melanoma. Oncogene 23: 6292-6298, 2004.
37. Wellbrock C, Ogilvie L, Hedley D, et al: V599EB-RAF is an oncogene in melanocytes. Cancer Res 64: 2338-2342, 2005.
38. Ahmad T and Eisen T: Kinase inhibition with BAY 43-9006 in renal carcinoma. Clin Cancer Res 10: S6388-S6392, 2004.
39. Lyons JF, Wilhelm S, Hibner B and Bollag G: Discovery of a novel Raf kinase inhibitor. Endocr Relat Cancer 8: 219-225, 2001.
40. Hearing VJ and Tsukamoto K: Enzymatic control of pigmentation in mammals. FASEB J 5: 2902-2909, 1991.
41. Levine N, Sheftel SN, Eytan T, et al: Induction of skin tanning by subcutaneous administration of a potent synthetic melanotropin. JAMA 266: 2730-2736, 1991.
42. Englaro W, Rezzonico R, Durand-Clement M, Lallemand D, Ortonne JP and Balotti R: Mitogen-activated protein kinase pathway and AP-1 are activated during cAMP-induced melanogenesis in B-16 melanoma cells. J Biol Chem 270: 24315-24320, 1995.
43. Hunt G, Todd C, Cresswell JE and Thody AJ: Alpha-melanocyte stimulating hormone and its analogue Nle4DPhe7 alpha-MSH affect morphology, tyrosinase activity and melanogenesis in cultured human melanocytes. J Cell Sci 107: 205-211, 1994.
44. Morvan D, Demidem A, Papon J, De Latour M and Madelmont JC: Melanoma tumors acquire a new phospholipids metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. Cancer Res 62: 1890-1897, 2002.
45. Demidem A, Morvan D, Papon J, De Latour M and Madelmont JC: Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Cancer Res 61: 2294-2300, 2001.
46. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K and Fujita T: Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetylarbamoyl) fumagillol (TNP-470; AGM-1470). Cancer Res 53: 4262-4267, 1993.
47. Figg WD, Pluda JM, Lush RM, Saville MW, Wyvill K, Reed E and Yarchoan R: The pharmacokinetic profile of TNP-470, a new angiogenesis inhibitor. Pharmacotherapy 17: 91-97, 1997.
48. Bhargava P, Marshall JL, Rizvi N, et al: A phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin Cancer Res 5: 1989-1995, 1999.
49. Moore JD, Dezube BJ, Gill P, Zhou X-J, Acosta EP and Sommadossi J-P: Phase I dose escalation pharmacokinetics of O-(chloroacetylcarbamoyl) fumagillol (TNP-470) and its metabolites in AIDS patients with Kaposi's sarcoma. Cancer Chemother Pharmacol 46: 173-179, 2000.
50. Recchia F, De Filippis S, Rosselli M, Saggio G, Cesta A, Fumagalli L and Rea S: Phase 1B study of subcutaneously administered interleukin 2 in combination with 13-cis retinoic acid as maintenance therapy in advanced cancer. Clin Cancer Res 7: 1251-1257, 2001.